Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech Reveals Positive Data For Stelara Rival

Results For AVT04 Ustekinumab Biosimilar Come Ahead Of Oaktree SPAC Merger Vote

Executive Summary

Alvotech has reported positive results from a study for its AVT04 proposed biosimilar ustekinumab rival to Stelara. The news comes ahead of a key vote on Alvotech’s SPAC merger with Oaktree Capital Management that will take the company public.

You may also be interested in...



Stada And Alvotech Launch Higher-Strength Adalimumab In Europe

Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.

What’s Next? Five Things To Look Out For In June

In June, Medicines for Europe will host its annual and legal affairs conferences in Barcelona, while on the commercial side Hikma’s CEO Siggi Olafsson is to resign from the London-listed company.

Alvotech Could Upend Expectations For US Humira Biosimilars

In the second part of an exclusive two-part interview with Generics Bulletin, Alvotech founder and chairman Robert Wessman sets out the firm’s expectations for its rival to Humira, as Alvotech continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel